Introduction: There is a need for ADC payloads with an improved therapeutic index, consequently we have coupled potent and selective inhibitors of NMT to trastuzumab to test their potential in both in ...
You do not currently have access to this content.
Background: LIV-1, also known as SLC39A6 or ZIP6, is a transmembrane protein belonging to the zinc transporter family. LIV-1 is a promising target for antibody-drug conjugate (ADC) therapy due to its ...
Background: Activating RET alterations drive oncogenic signaling in lung, thyroid, and other solid tumors.Until recently, only two RET tyrosine kinase inhibitor (TKI), BLU-667 and LOXO-292, had ...
Abstract. High-throughput screening (HTS) of cereblon (CRBN) molecular glue (MG)-biased libraries remains a key strategy for proof-of-concept studies and hit identification against emerging targets.
Cancer Discov (2026) 16 (7): OF1.
Cancer Discov (2026) 16 (7): OF1.
Cancer Discov (2026) 16 (7): OF1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results